GENE ONLINE|News &
Opinion
Blog

2021-07-18| Asia-PacificIPO

Could this Biotech be the First Billion-Dollar Hong Kong Startup to Go Public?

by Tyler Chen
Share To

Hong Kong’s Prenetics might be the first billion-dollar Hong Kong startup to go public. It is reported that Prenetics is planning a merger with a special purpose acquisition company (SPAC) called Artisan Acquisition (Artisan) by the end of 2021, for a value estimated to be over $1.3 billion.

Artisan has already raised $339 million in its initial public offering (IPO) and has obtained $60 million through forward purchase agreements with Aspex and PAG. However, it should be noted that it is not a done deal yet due to several factors that will come into play.

 

SPAC Explained

SPAC is a relatively new way to go public. The SPACs will go through the traditional IPO process to raise money and only use them to acquire or merge with a private firm. By doing so, the acquired company can evade the IPO process and be listed on the board through the SPAC’s shell. As a result, there has been an increasing number of SPAC deals in the biotech industry.

 

Prenetics’ Biggest Strength

Prenetics is well-known in the diagnostic and genetic testing industry, especially during the COVID-19 pandemic. The firm has installed COVID-19 screening devices in Hong Kong International airport and the London Heathrow Airport to accelerate the testing process of travelers.

Other than that, Prenetics in April announced a 3-year collaboration with the Oxford University to further develop Oxford’s rapid molecular testing technology for infectious diseases to deliver fast and accurate molecular testing globally.

Related Article: Oxford, Prenetics Join Forces To Scale Award-Winning Rapid Molecular Testing Technology

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Prenetics Announces Acquisition of ACT Genomics, Aiming for the Multi-billion Market of Precision Oncology
2022-12-21
CK Life Sciences and CK Hutchison Invest in Taiwanese Liquid Biopsy Candidate
2022-07-26
Human Longevity Plans to Merge With Blank Check Company to Go Public
2022-06-22
LATEST
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
2023-03-22
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Comparing ESG Regulations in the U.S., the U.K., and the EU
2023-03-21
See-Mode Technologies Secures Regulatory Approvals for its AI-powered Software that Automatically Analyses and Reports Breast & Thyroid Ultrasound Scans in Australia and New Zealand
2023-03-21
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
Scroll to Top